KRBP Stock Overview
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Kiromic BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.91 |
| 52 Week High | US$8.97 |
| 52 Week Low | US$0.16 |
| Beta | 2.01 |
| 1 Month Change | 95.96% |
| 3 Month Change | 45.50% |
| 1 Year Change | -24.22% |
| 3 Year Change | -98.89% |
| 5 Year Change | n/a |
| Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year
Oct 06Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma
Jul 12Kiromic expands in-house cell therapy manufacturing facility, names new COO
Jun 07Kiromic BioPharma files two IND applications for CAR-T therapy in cancer
Dec 17Kiromic BioPharma reports Q3 results
Nov 30Shareholder Returns
| KRBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 28.2% | -5.0% | -3.5% |
| 1Y | -24.2% | -1.7% | 20.2% |
Return vs Industry: KRBP underperformed the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: KRBP underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| KRBP volatility | |
|---|---|
| KRBP Average Weekly Movement | 35.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KRBP's share price has been volatile over the past 3 months.
Volatility Over Time: KRBP's weekly volatility (35%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 35 | Pietro Bersani | kiromic.com |
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L.
Kiromic BioPharma, Inc. Fundamentals Summary
| KRBP fundamental statistics | |
|---|---|
| Market cap | US$3.62m |
| Earnings (TTM) | -US$23.50m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs KRBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.50m |
| Earnings | -US$23.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -18.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -153.5% |
How did KRBP perform over the long term?
See historical performance and comparison